optimizing the use of endocrine therapy partners in mbc
Published 6 years ago • 43 plays • Length 6:25Download video MP4
Download video MP3
Similar videos
-
9:18
monarch 3: abemaciclib with endocrine therapy for mbc
-
6:18
hr mbc: factors in selecting cdk4/6 inhibitions
-
4:01
duration of endocrine therapy in breast cancer
-
7:40
sequencing of therapy in r/r her2 mbc
-
8:24
cdk4/6 inhibition in hormone receptor-positive mbc
-
5:03
role of fulvestrant monotherapy in hr mbc
-
10:02
breast cancer: extended adjuvant endocrine therapy
-
1:13
dr. mamounas on the role of extended adjuvant endocrine therapy in er breast cancer
-
5:36
hormone receptor-positive mbc: neoadjuvant therapy
-
30:20
optimizing adjuvant endocrine therapy for early breast cancer
-
4:22
how to use endocrine therapy in premenopausal women with er metastatic breast cancer
-
7:45
do cdk4/6 inhibitors impact later therapy in hr mbc?
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
6:09
adjuvant endocrine therapy for breast cancer: optimal durations and regimens
-
3:45
endocrine therapy benefits for stage 1 breast cancer
-
19:11
novel strategies for endocrine therapy: can we do better?
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
7:27
developments in chemotherapy for hr mbc
-
4:45
advances and considerations in the treatment and management of hr , her2-, advanced breast cancer